CLDX Stock Analysis: Buy, Sell, or Hold?
CLDX - Celldex Therapeutics, Inc
$41.71
0.15 (0.36%)
â˛
5d:
+9.59%
30d:
+7.0%
90d:
+25.18%
WAIT
LOW Confidence
Analysis Updated: Aug 7, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When CLDX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CLDX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CLDX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: CLDX is currently trading at $41.71, which is considered fair relative to its 30-day fair value range of $35.42 to $38.61.
Technical Outlook: Technically, CLDX is in a uptrend. The price is approaching resistance at $42.92. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: CLDX scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $57.07 (+36.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CLDX is in a uptrend. The price is approaching resistance at $42.92. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: CLDX scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $57.07 (+36.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$35.42 -
$38.61
Company Quality Score
36/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 36.8% below Wall St target ($57.07)
- WARNING: Composite score 36/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$35.42 -
$38.61
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$35.00
Resistance Level
$42.92
Current Trend
Uptrend
Technical data as of
Aug 7, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-9.59
Wall Street Target
$57.07
(+36.8%)
Revenue Growth (YoY)
-97.8%
Share & Embed Analysis
Last updated: August 10, 2026 1:11 AM ET
Data refreshes hourly during market hours. Next update: 2:11 AM
Data refreshes hourly during market hours. Next update: 2:11 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CLDX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals âĻ |
STRONG BUY
30 analysts |
$376 | 55 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$431 | 43 HOLD |
|
VRTX
Vertex Pharmaceuticals IâĻ |
BUY
34 analysts |
$559 | 43 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$309 | 63 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$198 | 34 SELL |
